Loading
After nine years the antibody maintenance group had gone more than six years longer before their lymphoma returned, and exactly as many people in each group were alive.
The final analysis of PRIMA after nine years of follow-up, with a data cut-off of 31 December 2016. 1,018 patients had been randomised to rituximab maintenance (505) or observation (513); 607 (59.6 per cent) consented to extended follow-up.
Median progression-free survival was 10.5 years in the maintenance arm against 4.1 years in the observation arm (hazard ratio 0.61, 95 per cent confidence interval 0.52 to 0.73). Overall survival did not differ (p = 0.7948), with ten-year estimates of approximately 80 per cent in both arms. No new safety signals were observed.
The number to give a patient deciding about maintenance: a median of six and a half extra years before the next treatment, and no difference in how long they live. Both halves belong in the conversation.
The single most used prognostic marker in follicular lymphoma, and the reason a relapse at 20 months is handled differently from one at 30 months. It is now a standard stratification factor and a standard eligibility criterion in trials of the disease.
The trial that made two years of rituximab maintenance a routine offer after first-line immunochemotherapy for follicular lymphoma with a high tumour burden.
Shares Gilles Salles, Maintenance and consolidation in lymphoma: where it works and where it does not, LYSA (The Lymphoma Study Association), Maintenance therapy and the tag lymphoma-evidence.
Shares Gilles Salles, Maintenance and consolidation in lymphoma: where it works and where it does not, LYSA (The Lymphoma Study Association), Maintenance therapy and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares LYSA (The Lymphoma Study Association), Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study, POD24: progression of follicular lymphoma within two years, and why it changes the plan, LYSA (The Lymphoma Study Association), CD20 and the tag lymphoma-evidence.
Shares CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Toxicity and quality of life are undervalued and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Maintenance therapy, CD20, Rituximab and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Patients lack understanding, navigation and agency, CD20, Rituximab and the tag lymphoma-evidence.